| ROYALTY-PHARMA-INVESTMENTS-2019-ICAV |
ROYALTY-PHARMA-INVESTMENTS-2019-ICAV |
92%
|
Pursuant to the Royalty Purchase Agreement, Royalty Pharma purchased from the Company the right to receive tiered revenue payments with respect to worldwide net product sales of (i) RMC-6236 Products… |
| RPRX |
Royalty Pharma plc |
92%
|
Reciprocal relationship from RPRX graph: Reciprocal relationship from RVMD graph: Pursuant to the Royalty Purchase Agreement, Royalty Pharma purchased from the Company the right to receive tiered rev… |
| RPRX |
Royalty Pharma plc |
92%
|
Pursuant to the Royalty Purchase Agreement, Royalty Pharma purchased from the Company the right to receive tiered revenue payments with respect to worldwide net product sales of (i) RMC-6236 Products… |
| ERAS |
Erasca, Inc. |
85%
|
Reciprocal relationship from ERAS graph: the Company’s ability to successfully defend against allegations raised by, or any future litigation initiated by, Revolution Medicines (RevMed) that ERAS-001… |
| SNYNF |
Sanofi |
72%
|
ement was terminated in June 2023, and Sanofi has no further reimbursement obligations following this termination. To date, we have devoted substantially all of our resources to organizing and staffi… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RVMD graph: ement was terminated in June 2023, and Sanofi has no further reimbursement obligations following this termination. T… |
| AETHON-THERAPEUTICS-INC |
AETHON-THERAPEUTICS-INC |
62%
|
Item 8 of this Annual Report on Form 10-K. Aethon Collaboration In March 2024, we entered into a collaboration agreement with Aethon Therapeutics, Inc. (Aethon) pursuant to which Aethon is conducting… |
| CM-LIFE-SCIENCES-III-INC |
CM-LIFE-SCIENCES-III-INC |
62%
|
ted- average remaining useful life (in thousands) (in years) In-process research and development — RAS Programs $ 55,800 $ — $ 55,800 n/a Developed technology — tri-complex platform 7,480 ( 7,480 ) —… |
| COMPANY-LLC |
COMPANY-LLC |
62%
|
ific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Nonrefundable advance payments for goods or services to be received in future per… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
ance with regulatory standards and requirements and insider trading. We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may… |
| EQUINITI-TRUST-COMPANY-LLC |
EQUINITI-TRUST-COMPANY-LLC |
62%
|
ance with regulatory standards and requirements and insider trading. We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may… |
| ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC |
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC |
62%
|
, the associated royalty rates would be lower for each of the net sales tiers. Additionally, the Royalty Purchase Agreement provides for an upward adjustment to the Royalty Payment rates in the years… |
| USA-LLC |
USA-LLC |
62%
|
c tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Nonrefundable advance payments for goods or services to be received in future period… |
| WARP-DRIVE-BIO-INC |
WARP-DRIVE-BIO-INC |
62%
|
he development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have… |
